India Pharma Outlook Team | Thursday, 23 July 2026
The Prostate Cancer Treatment from Pfizer has taken a major step toward expanded use in the US.
The company has received FDA Priority Review for its supplemental New Drug Application. The application seeks approval for Talzenna in combination with Xtandi.
The treatment is intended for adults with Metastatic Castration-Sensitive Prostate Cancer who have HRR Gene Mutations. FDA is expected to make its decision in the fourth quarter of 2026.
The Priority Review follows positive results from the TALAPRO-3 study. The trial showed the drug combination significantly reduced the risk of disease progression or death. If approved, the expanded label could give eligible patients another targeted treatment option earlier in their disease journey.
“For men living with metastatic prostate cancer, intervening during the hormone-sensitive stage represents an important opportunity to delay progression before the disease becomes more difficult to manage,” said Jeff Legos, Chief Oncology Officer, Pfizer.
Pfizer's application is supported by data from the global Phase 3 TALAPRO-3 trial. The study compared Talzenna plus Xtandi with placebo plus Xtandi in patients with metastatic castration-sensitive prostate cancer carrying HRR gene mutations.
The combination met the study's primary endpoint. It reduced the risk of disease progression or death by 52 percent compared with Xtandi alone.
The trial also showed improvements in several secondary endpoints. Patients receiving the combination experienced a longer period before their cancer worsened. The treatment also delayed the need for chemotherapy in many patients.
The overall safety profile remained consistent with the known safety of both medicines. No unexpected safety concerns were identified during the trial.
Priority Review is granted to medicines that could provide significant improvements in treating serious diseases. It shortens the FDA's review timeline compared with the standard review process.
Talzenna is a PARP inhibitor that targets cancer cells with defects in DNA repair pathways. Xtandi blocks androgen receptors that help prostate cancer grow. Together, the medicines attack the disease through different mechanisms.
The combination is already approved in the US for certain patients with metastatic castration-resistant prostate cancer and HRR gene mutations. Pfizer is now seeking to expand its use to patients at an earlier stage of advanced disease.
The same application is also under review by European regulators. A positive decision in both regions would broaden access to the therapy for eligible patients.
Also Read: How AI Can Power Target Identification and Disease Mapping
Prostate cancer remains one of the most common cancers among men worldwide. Patients with HRR gene mutations often have fewer treatment options as the disease advances.
Earlier access to targeted therapies may help delay disease progression and extend the time before patients require more intensive treatments.
The FDA's Priority Review brings Pfizer one step closer to expanding its oncology portfolio. It could also improve treatment choices for patients with advanced prostate cancer.
